Nature Communications (Oct 2022)
Development of intravenously administered synthetic RNA virus immunotherapy for the treatment of cancer
- Edward M. Kennedy,
- Agnieszka Denslow,
- Jacqueline Hewett,
- Lingxin Kong,
- Ana De Almeida,
- Jeffrey D. Bryant,
- Jennifer S. Lee,
- Judy Jacques,
- Sonia Feau,
- Melissa Hayes,
- Elizabeth L. McMichael,
- Daniel Wambua,
- Terry Farkaly,
- Amal A Rahmeh,
- Lauren Herschelman,
- Danielle Douglas,
- Jacob Spinale,
- Sanmit Adhikari,
- Jessica Deterling,
- Matt Scott,
- Brian B. Haines,
- Mitchell H. Finer,
- Ted T Ashburn,
- Christophe Quéva,
- Lorena Lerner
Affiliations
- Edward M. Kennedy
- Oncorus, Inc.
- Agnieszka Denslow
- Oncorus, Inc.
- Jacqueline Hewett
- Oncorus, Inc.
- Lingxin Kong
- Oncorus, Inc.
- Ana De Almeida
- Oncorus, Inc.
- Jeffrey D. Bryant
- Oncorus, Inc.
- Jennifer S. Lee
- Oncorus, Inc.
- Judy Jacques
- Oncorus, Inc.
- Sonia Feau
- Oncorus, Inc.
- Melissa Hayes
- Oncorus, Inc.
- Elizabeth L. McMichael
- Oncorus, Inc.
- Daniel Wambua
- Oncorus, Inc.
- Terry Farkaly
- Oncorus, Inc.
- Amal A Rahmeh
- Oncorus, Inc.
- Lauren Herschelman
- Oncorus, Inc.
- Danielle Douglas
- Oncorus, Inc.
- Jacob Spinale
- Oncorus, Inc.
- Sanmit Adhikari
- Oncorus, Inc.
- Jessica Deterling
- Oncorus, Inc.
- Matt Scott
- Oncorus, Inc.
- Brian B. Haines
- Oncorus, Inc.
- Mitchell H. Finer
- Oncorus, Inc.
- Ted T Ashburn
- Oncorus, Inc.
- Christophe Quéva
- Oncorus, Inc.
- Lorena Lerner
- Oncorus, Inc.
- DOI
- https://doi.org/10.1038/s41467-022-33599-w
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 13
Abstract
The development of neutralizing antibodies can limit the therapeutic effectiveness of systemically administered oncolytic viruses (OV). Here, to enable repeated intravenous administration, the authors report the development of synthetic RNA viruses formulated within lipid nanoparticles, showing anti-tumor efficacy even in the presence of OV neutralizing antibodies.
